Background Molnupiravir has been considered a promising candidate for COVID-19. Its
efficacy and safety in non-severe COVID-19 patients and the differences between patients …

Background Throughout the time of the global pandemic of SARS-CoV-2 virus, there has
been a compelling necessity for the development of effective antiviral agents and …

Background At the peak of the coronavirus disease 2019 (COVID-19) pandemic, the need
for an orally administered agent to prevent the progression of acute respiratory syndrome …

Despite the progress in the management of COVID-19, effective oral antiviral agents are still
lacking. In the present review, the potential beneficial effects of molnupiravir in the …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral …

Background and aims Molnupiravir is a newer oral antiviral drug that has recently been
tested in COVID-19. We aim to conduct a systematic review of literature to find out the …

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In
this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …

Since the start of the severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)
pandemic, several treatments have been proposed to cure coronavirus disease 2019 …

Background The study was aimed at encapsulating the evidence of in vitro and in vivo
antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2 …